Protocadherin γ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth

Zhang,Xueyan; Takata,Katsuyoshi; Cui,Wei; Miyata‑Takata,Tomoko; Sato,Yasuharu; Noujima‑Harada,Mai; Yoshino,Tadashi

doi:10.3892/mmr.2016.5808

Protocadherin γ A3 is expressed in follicular lymphoma irrespective of BCL2 status and is associated with tumor cell growth

Authors:
- Xueyan Zhang
- Katsuyoshi Takata
- Wei Cui
- Tomoko Miyata‑Takata
- Yasuharu Sato
- Mai Noujima‑Harada
- Tadashi Yoshino
View Affiliations

Affiliations: Department of Pathology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700‑8558, Japan
Published online on: October 5, 2016 https://doi.org/10.3892/mmr.2016.5808
Pages: 4622-4628
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protocadherin genes (PCDHs) have been suggested to act as tumor suppressor genes in various tumor types. Previous studies have demonstrated the upregulation of certain PCDH‑γ subfamily genes in nodal and duodenal follicular lymphoma (FL) using gene expression analyses. However, the mechanisms and associated molecular function of PCDH‑γ subfamily gene upregulation in FL remain to be elucidated. The present study examined the expression of PCDHGA3, an upregulated PCDH‑γ gene subfamily member, in B‑cell lymphoma 2 (BCL2)‑positive and ‑negative FL, and evaluated its association with tumor cell proliferation in an FL‑derived cell line. Immunohistochemical analysis demonstrated that the majority of FL grade 1‑2 samples (19/20; 95%) and over half of grade 3A FL samples (5/9; 56%) were PCDHGA3‑positive, whereas only 1/17 reactive lymphoid hyperplasia samples was positive. Notably, this positivity was widely observed in samples of BCL2‑negative FL (13/15; 87%) and FL with diffuse area (10/10; 100%). The FL‑derived cell line FL18 exhibited strong PCDHGA3 expression, similar to the patient samples, and its proliferation was suppressed by PCDHGA3 gene knockdown. Genes expressed concomitantly with PCDHGA3 were selected from gene expression data, and TNFRSF6B, a member of the tumor necrosis factor receptor superfamily, was among the top five most strongly correlated genes. Coexpression of TNFRSF6B and PCDHGA3 was observed immunohistochemically in FL18 cells, suggesting potential cooperation in tumor cell maintenance. In conclusion, the results of the present study indicated that PCDHGA3 was expressed in FL irrespective of BCL2 status and grading and was associated with cell proliferation. Further studies involving molecular genetic analyses are required to elucidate the mechanisms underlying the activity of PCDHGA3 in FL.

View Figures

View References

1	NL SS Harris, Jaffe ES, Ott G, Nathwani BN, et al: World Health Organization Classification of Tumours, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th. International Agency for Research on Cancer (IARC); Lyon: pp. 220–226. 2008
2	Lai R, Arber DA, Chang KL, Wilson CS and Weiss LM: Frequency of bcl-2 expression in non-Hodgkin's lymphoma: A study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. Mod Pathol. 11:864–869. 1998.PubMed/NCBI
3	Takata K, Tanino M, Ennishi D, Tari A, Sato Y, Okada H, Maeda Y, Goto N, Araki H, Harada M, et al: Duodenal follicular lymphoma: Comprehensive gene expression analysis with insights into pathogenesis. Cancer Sci. 1015:608–615. 2014. View Article : Google Scholar
4	Morishita H and Yagi T: Protocadherin family: Diversity, structure, and function. Curr Opin Cell Biol. 19:584–592. 2007. View Article : Google Scholar : PubMed/NCBI
5	Chen WV, Alvarez FJ, Lefebvre JL, Friedman B, Nwakeze C, Geiman E, Smith C, Thu CA, Tapia JC, Tasic B, et al: Functional significance of isoform diversification in the protocadherin gamma gene cluster. Neuron. 75:402–409. 2012. View Article : Google Scholar : PubMed/NCBI
6	Yu J, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, et al: PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 27:4657–4665. 2008. View Article : Google Scholar : PubMed/NCBI
7	de Tayrac M, Etcheverry A, Aubry M, Saïkali S, Hamlat A, Quillien V, Le Treut A, Galibert MD and Mosser J: Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes and Cancer. 48:55–68. 2009. View Article : Google Scholar : PubMed/NCBI
8	Haruki S, Imoto I, Kozaki K, Matsui T, Kawachi H, Komatsu S, Muramatsu T, Shimada Y, Kawano T and Inazawa J: Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous-cell carcinoma. Carcinogenesis. 31:1027–1036. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ying J, Gao Z, Li H, Srivastava G, Murray PG, Goh HK, Lim CY, Wang Y, Marafioti T, Mason DY, et al: Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies. Br J Haematol. 136:829–832. 2007. View Article : Google Scholar : PubMed/NCBI
10	Hayashi E, Takata K, Sato Y, Tashiro Y, Tachiyama Y, Sawada-Kitamura S, Hiramatsu Y, Sugiguchi S, Nose S, Hirokawa M, et al: Distinct morphologic, phenotypic, and clinical-course characteristics of indolent peripheral T-cell lymphoma. Hum Pathol. 44:1927–1936. 2013. View Article : Google Scholar : PubMed/NCBI
11	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
12	Takata K, Sato Y, Nakamura N, Tokunaka M, Miki Y, Kikuti Y Yukie, Igarashi K, Ito E, Harigae H, Kato S, et al: Duodenal follicular lymphoma lacks AID but expresses BACH2 and has memory B-cell characteristics. Mod Pathol. 26:22–31. 2013. View Article : Google Scholar : PubMed/NCBI
13	Curtin JF and Cotter TG: Live and let die: Regulatory mechanisms in Fas-mediated apoptosis. Cell Signal. 15:983–992. 2003. View Article : Google Scholar : PubMed/NCBI
14	Zheng L, Sharma R, Gaskin F, Fu SM and Ju ST: A novel role of IL-2 in organ-specific autoimmune inflammation beyond regulatory T cell checkpoint: Both IL-2 knockout and Fas mutation prolong lifespan of Scurfy mice but by different mechanisms. J Immunol. 179:8035–8041. 2007. View Article : Google Scholar : PubMed/NCBI
15	Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V, Gascoyne RD, Chan WC, Braziel RM, Rimsza LM, et al: Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 114:826–834. 2009. View Article : Google Scholar : PubMed/NCBI
16	Masir N, Campbell LJ, Goff LK, Jones M, Marafioti T, Cordell J, Clear AJ, Lister TA, Mason DY and Lee AM: BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations. Br J Haematol. 144:716–725. 2009. View Article : Google Scholar : PubMed/NCBI
17	Zamo A, Erdini F, Malerba G and Chilosi M: Lack of expression of TUBB3 characterizes both BCL2-positive and BCL2-negative follicular lymphoma. Mod Pathol. 27:808–813. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wu Y, Guo E, Yu J, Xie Q and Chen J: High DcR3 expression predicts stage pN2 in gastric cancer. Hepatogastroenterology. 54:2172–2176. 2007.PubMed/NCBI
19	Connor JP and Felder M: Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol. 111:330–335. 2008. View Article : Google Scholar : PubMed/NCBI
20	Weissinger D, Tagscherer KE, Macher-Göppinger S, Haferkamp A, Wagener N and Roth W: The soluble Decoy Receptor 3 is regulated by a PI3K-dependent mechanism and promotes migration and invasion in renal cell carcinoma. Mol Cancer. 12:1202013. View Article : Google Scholar : PubMed/NCBI
21	Bedewy AM, Elgammal MM, Bedewy MM and El-Maghraby SM: Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma. Ann Hematol. 92:1359–1367. 2013. View Article : Google Scholar : PubMed/NCBI